Core Viewpoint - Annovis Bio, Inc. is hosting a live webcast to provide updates on its clinical trials for neurodegenerative diseases, specifically Alzheimer's disease and Parkinson's disease, while addressing questions from patients and caregivers [1][2][3]. Group 1: Webcast Details - The webcast will feature CEO Maria Maccecchini providing updates on the ongoing Phase 3 trial for Alzheimer's disease, as well as plans for the Phase 3 trial for Parkinson's disease and Open Label Extension studies [2]. - A short presentation will highlight recent achievements, followed by a Q&A session where attendees can submit questions in advance [2]. Group 2: Company Mission and Approach - Annovis Bio is focused on addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's, utilizing an innovative approach that targets multiple neurotoxic proteins to restore brain function and improve patients' quality of life [4]. - The company emphasizes transparency and patient-centric communication, aiming to address questions from patients, families, and caregivers [3]. Group 3: Investor Engagement - Investors and shareholders are encouraged to sign up for press releases and industry updates through the company's email alerts [5]. - The updated investor website offers comprehensive access to company news, financial reports, and other key information [5].
Annovis to Host Patients' Live Forum on February 27, 2025